Condition
Crigler-Najjar Syndrome
Total Trials
7
Recruiting
2
Active
2
Completed
3
Success Rate
60.0%-27% vs avg
Key Insights
Highlights
Success Rate
60% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
28.6%
2 terminated out of 7 trials
Success Rate
60.0%
-26.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 3 completed with results
Key Signals
60% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (2)
P 1 (1)
P 2 (1)
Trial Status
Completed3
Recruiting2
Terminated2
Trial Success Rate
60.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (7)
Showing 7 of 7 trials
NCT05687474Completed
Baby Detect : Genomic Newborn Screening
NCT06518005Phase 2RecruitingPrimary
Efficacy and Safety of GNT0003 Following Imlifidase Pre-treatment in Severe Crigler-Najjar Syndrome
NCT03343756Terminated
HepaStem Long-Term Safety Registry
NCT03466463Not ApplicableRecruitingPrimary
Gene Therapy for Severe Crigler Najjar Syndrome
NCT03223194Phase 1TerminatedPrimary
Gene Transfer Clinical Study in Crigler-Najjar Syndrome
NCT03078881CompletedPrimary
Clinical Assessment Study in Crigler-Najjar Syndrome
NCT00461799Not ApplicableCompletedPrimary
Orlistat Treatment of Crigler-Najjar Disease
Showing all 7 trials